Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.51 |
| ▸ | F10 | P00742 | 4/20 | 0.38 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845254 | 1.00 | LPAR1 (0.51) | LPAR1F10GPR132CYP4F2CYP4A11 | |
| SCHEMBL13276433 | 1.00 | LPAR1 (0.51) | LPAR1F10GPR132CYP4F2CYP4A11 | |
| SCHEMBL12095349 | 0.92 | LPAR1 (0.58) | LPAR1F10GPR132CYP4F2CYP4A11 | |
| SCHEMBL12095350 | 0.92 | LPAR1 (0.58) | LPAR1F10GPR132CYP4F2CYP4A11 | |
| SCHEMBL12095348 | 0.92 | LPAR1 (0.58) | LPAR1F10GPR132CYP4F2CYP4A11 | |
| SCHEMBL1809808 | 0.89 | LPAR1 (0.61) | LPAR1GPR132L3MBTL1 | |
| SCHEMBL1812191 | 0.87 | LPAR1 (0.66) | LPAR1F10GPR132PDE4D | |
| SCHEMBL1812195 | 0.87 | LPAR1 (0.66) | LPAR1F10GPR132PDE4D | |
| SCHEMBL1812192 | 0.87 | LPAR1 (0.66) | LPAR1F10GPR132PDE4D | |
| SCHEMBL1809796 | 0.86 | LPAR1 (0.51) | LPAR1F10GPR132CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | LPAR1 4/4885F10 112/4885GPR132 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.